Priligy 60 mg is not a premium version that every patient should prefer. The Irish product information directs treatment to start at 30 mg. A clinician may consider 60 mg when benefit is insufficient and the lower dose has been tolerated without reactions that make escalation inappropriate.
The decision is a balance, not a test of willingness to take more medicine. A higher dose can offer additional average benefit while also increasing unwanted effects. Taking two tablets after a disappointing attempt bypasses both the assessment and the dosing-frequency restriction.
What the controlled evidence compares
An integrated analysis of phase 3 trials found improvement with both on-demand doses compared with placebo. At week 12, arithmetic mean intravaginal ejaculation latency was 3.1 minutes with 30 mg, 3.6 minutes with 60 mg and 1.9 minutes with placebo. Baseline means were approximately 0.9 minutes across groups.
These figures are group averages from selected trial populations, not an individual forecast. They do not mean that increasing the dose adds exactly half a minute for every patient, or that the difference between two averages determines the best personal choice.
The product information also reports dose-related adverse reactions:
| Reaction reported in phase 3 trials | 30 mg on demand | 60 mg on demand |
|---|---|---|
| Nausea | 11.0% | 22.2% |
| Dizziness | 5.8% | 10.9% |
| Headache | 5.6% | 8.8% |
| Diarrhea | 3.5% | 6.9% |
Trial percentages describe the groups studied. They are not a guarantee that a particular person will or will not experience a reaction, and they do not capture every possible adverse effect.
Which reactions argue against escalation?
The label's escalation conditions exclude moderate or severe adverse reactions and symptoms suggesting impending fainting. An orthostatic reaction on the starting dose is also a reason not to increase to 60 mg.
Tell the prescriber about lightheadedness, sweating, marked weakness or feeling close to losing consciousness. Do not minimize those symptoms because the tablet helped ejaculation or because you want a stronger effect. Tolerability is part of the dose decision, not an inconvenience to report only after escalation.
If a reaction is concerning, obtain medical advice before another dose. A planned review after several uses is not a requirement to repeat an unsafe experience until enough attempts have been recorded.
Other medicines can change the allowable plan
The medical review checks more than whether 30 mg helped. Some interactions can increase dapoxetine exposure, restrict the dose or make the medicine unsuitable. Relevant liver impairment, a fainting history and particular heart conditions also affect eligibility.
Bring the complete medication list, including occasional prescriptions and supplements. Do not reduce or stop another medicine to qualify for a higher Priligy strength. A pharmacist or prescriber needs to evaluate the actual combination rather than a broad category such as "antibiotics" or "vitamins."
A patient who tolerates 30 mg when taking one set of medicines may need reassessment after a new prescription. Previous tolerance does not permanently authorize the higher strength.
Separate insufficient benefit from an inadequate trial
An unsatisfactory attempt can reflect timing, an unaddressed erection problem, expectations or the fact that the treatment is not a good fit. Increasing the milligrams does not automatically solve those issues.
For the review, note:
- Whether the prescribed dose and timing were followed.
- Whether control changed, not only whether the encounter lasted longer.
- Any symptoms after the tablet, including those outside sexual activity.
- Whether erections were maintained before ejaculation.
- What result would be worthwhile enough to continue treatment.
The clinician can then distinguish a reasonable escalation discussion from a need to reconsider diagnosis or treatment choice. If 30 mg already gives a useful, tolerable result, more medicine is not automatically better.
The frequency limit does not change
Under the cited product information, neither strength is to be taken more than once in 24 hours. A decision to prescribe 60 mg does not authorize same-day top-ups or repeated tablets when plans change.
The appropriate question is whether a supervised change improves the overall balance for this patient. The strongest tablet is not necessarily the most usable treatment, and a larger trial average is not sufficient reason to accept an adverse effect that undermines safety or everyday function.